Guizhou Bailing Group Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 1999, Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) has grown from a traditional Chinese medicine R&D and manufacturing outfit into a publicly traded company after its June 2010 listing on the Shenzhen Stock Exchange, operating across four segments-Industrial, Commerce, Medical Institutions and Others-with roughly 6,586 employees by 2025; strategic moves include a ¥500 million biotech acquisition in 2023 and a research partnership the same year to push innovative drug development, while sustainability commitments report recycling up to 2 million tons of wastewater and using 100,000 tons of waste residue annually alongside cultivation of over 200,000 mu (≈30,000 hectares) of medicinal herbs; financially the company had sales of CNY 2,101.58 million in the nine months to September 30, 2025 (down from CNY 2,775.41 million a year earlier) with net income of CNY 56.81 million (versus CNY 88.22 million), a market capitalization of approximately CN¥7.11 billion in late 2025, a 52‑week stock range of CN¥3.50-CN¥6.94, ongoing efforts to improve its debt-to-equity position, and a modest average Return on Equity of 0.17%, while revenue streams remain rooted in sales of core TCM products like Yindan Xinnaotong Soft Capsules, Kesuting Syrup and Capsules, Jin Gan Capsules and Wei C Yinqiao Tablets.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): Intro

• Founded: 1999
• IPO: June 2010 (Shenzhen Stock Exchange, 002424.SZ)
• Employees: ~6,586 (by 2025)
• 2023 acquisition: local biotech company for ¥500 million
• Strategic research alliance: partnered with a leading research university in 2023

History & Growth Milestones

• 1999: Company established with a TCM focus-R&D, production and sales.
• 2010: Successful IPO in June on Shenzhen Stock Exchange (002424.SZ), enabling capital expansion.
• 2010s-2020s: Expanded manufacturing footprint and distribution channels across hospitals, pharmacies and commerce platforms.
• 2023: Acquired a biotech company for ¥500 million to strengthen innovative drug pipelines.
• 2023: Formed a strategic research partnership with a leading university to co-develop therapeutic solutions.
• 2025: Workforce reached ~6,586 employees, reflecting operational scaling.

Ownership & Corporate Structure

• Listed public company with shares traded under 002424.SZ on Shenzhen Stock Exchange.
• Ownership mix typically includes institutional investors, retail shareholders and controlling shareholders (corporate filings should be consulted for current ownership percentages).
• Corporate governance: Board, management team overseeing Industrial, Commerce, Medical Institutions and Other operations.

Mission, R&D and Strategic Focus

• Mission: Advance traditional Chinese medicine and related healthcare products through integrated R&D, manufacturing and commercialization.
• R&D strategy: Combine in-house development with external partnerships-2023 university alliance and biotech acquisition to accelerate innovation.
• Product portfolio evolution: From classical TCM preparations to newer formulations and biologics enabled by the biotech acquisition.

How It Works - Operations & Business Segments

• Industrial: Manufacturing of TCM formulations, raw material processing, quality control and scale production for domestic distribution.
• Commerce: Sales through national distributor networks, retail pharmacies, e-commerce channels and export markets where applicable.
• Medical Institutions: Supplying hospitals, clinics and healthcare providers with prescription TCM products, injectables and standardized preparations.
• Others: Ancillary services, licensing, contract manufacturing and emerging biologics/innovative drug activities post-acquisition.

How Guizhou Bailing Makes Money - Revenue Streams

• Product sales: Core revenue from TCM finished products and formulations sold to distributors, retailers and medical institutions.
• Institutional contracts: Long-term supply agreements with hospitals and healthcare networks in the Medical Institutions segment.
• Commercial channels: Revenue from pharmacy chains, e-commerce and regional distributors in the Commerce segment.
• OEM/contract manufacturing: Industrial segment revenue from third-party manufacturing agreements.
• Licensing and technology transfers: Potential revenue from IP licensing and collaborative R&D outcomes (enhanced by 2023 acquisitions and partnerships).

Key Strategic Moves & Financial Implications

• IPO (2010): Provided capital for capacity expansion, R&D and market growth.
• ¥500M biotech acquisition (2023): Significantly increased capabilities in biologics/innovative drug development-expected to shift revenue mix over medium term toward higher-margin novel therapeutics.
• 2023 university partnership: Lowers R&D risk and accelerates clinical/translational activities, potentially unlocking new revenue and licensing income streams.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): History

• Founded as a regional pharma manufacturer; IPO on Shenzhen Stock Exchange (002424.SZ).
• Shifted from primarily traditional/OTC offerings to hospital-focused generics and APIs.
• Ongoing modernization and capacity investments to meet regulatory and quality standards.

• Publicly traded on the Shenzhen Stock Exchange under ticker 002424.SZ.
• Shareholder base: a mix of institutional investors, retail/individual shareholders and company insiders.
• Management and founder-related parties retain strategic stakes but do not constitute an overwhelming majority.

• Revenue drivers: sales of generic prescription drugs to hospitals, OTC consumer products, and sales of APIs to other manufacturers.
• Margins come from scale in manufacturing, product mix (higher-margin hospital generics), and supply agreements with regional hospitals and distributors.
• Capital allocation: reinvestment in production capacity, R&D for reformulations/approvals, and working-capital management to support distribution.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): Ownership Structure

• Mission and values: committed to research, development, production and sale of traditional Chinese medicine products to improve public health; emphasis on innovation, sustainability and social responsibility.
• Innovation moves: acquisition of a local biotech company in 2023 to strengthen capabilities in innovative drug development; R&D expenditure ~¥180 million in the latest fiscal year (2023) to accelerate new drug pipelines.
• Strategic partnerships: 2023 collaboration with a leading research university to co-develop therapeutic solutions and clinical research pathways.
• Sustainability commitments: annual recycling of up to 2 million tons of wastewater and utilization of ~100,000 tons of waste residue to minimize industrial impact.
• Honors and recognition: awarded titles including 'National Intellectual Property Advantage Enterprise' and 'National Model Collective for National Unity and Progress.'
• Herbal cultivation: owns over 200,000 mu (approximately 30,000 hectares) of medicinal herb cultivation bases, securing raw material supply and quality control.

• How it makes money: core revenue streams include TCM finished products (patented formulas and OTC medicines), bulk herb processing and sales, contract manufacturing, and increasingly biopharmaceuticals from its post-2023 biotech expansion.
• Operational model: vertical integration from own herb cultivation bases → GMP manufacturing facilities → domestic & export sales channels; strategic university and industry partnerships accelerate clinical validation and market entry for innovative products.
• Ownership profile (outline): publicly listed (SZSE: 002424.SZ) with mixed institutional and retail shareholders; major state/enterprise-linked stakeholders maintain strategic influence while management drives R&D and M&A to expand pipelines.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): Mission and Values

• Core mission elements: ensure drug quality and safety, expand access in domestic markets, support medical institutions, and invest in product innovation.
• Values: patient-first orientation, regulatory compliance, product diversity, and workforce development (≈6,586 employees).

• The company manufactures a comprehensive range of dosage forms: tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, oral liquids, medicinal wines and honey-based products.
• Clinical focus areas include cardiovascular, respiratory (cough & cold), gynecological and pediatric therapies, reflecting a mix of TCM and Western formulations.

• Robust distribution network covering the domestic market; products are sold across provinces nationwide (market presence in all 31 provincial-level divisions).
• Sales channels include direct hospital tenders, regional wholesalers, retail pharmacies and e-commerce platforms.

• Workforce: approximately 6,586 employees supporting production, quality control, sales and logistics.
• Facilities produce multiple dosage forms under GMP standards with capacity to supply both hospital tenders and over‑the‑counter retail segments.

• Recognized as a National Intellectual Property Advantage Enterprise.
• Awarded the National Model Collective for National Unity and Progress.
• Multiple regional quality and safety certifications and industry awards for product innovation and compliance.

• Revenue streams: product sales from Industrial and Commerce segments, institutional contracts from Medical Institutions, and ancillary income from licensing/R&D partnerships.
• Profitability drivers: branded OTC products, scale in hospital tender wins, and cost efficiencies from integrated manufacturing and distribution.
• Pricing mix: higher-margin OTC and branded TCM products vs. lower-margin tender-based institutional sales.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): How It Works

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) operates as a vertically integrated pharmaceutical and health-products company focused on traditional Chinese medicine (TCM) formulations, OTC health products, and related manufacturing and distribution. Its business model centers on R&D, production, brand marketing, and sales through hospital channels, pharmacies, and direct-to-consumer distribution.

• Primary revenue streams: manufacture and sale of TCM products, health supplements, and over-the-counter medicines.
• Channel mix: hospital procurement, retail pharmacies, e-commerce platforms, and regional distributors.
• R&D and IP: proprietary formulations and active efforts to protect and leverage intellectual property.

Key profit-generating products include:

• Yindan Xinnaotong Soft Capsules
• Kesuting Syrup and Capsules
• Jin Gan Capsules
• Wei C Yinqiao Tablets

Operational and financial characteristics that explain how the company makes money:

• Product portfolio breadth: multiple established TCM SKUs that generate recurring OTC and prescription sales.
• Margin drivers: pricing of branded TCM products, manufacturing efficiencies, and scale in core SKUs.
• Cost and profitability pressures: year-over-year revenue decline (CNY 2,101.58m vs. CNY 2,775.41m) and lower net income (CNY 56.81m vs. CNY 88.22m) compress margins and result in a low average ROE (~0.17%).
• Brand and IP leverage: honors and recognitions help support market access and trust-examples include "National Intellectual Property Advantage Enterprise" and "National Model Collective for National Unity and Progress."

For details on corporate mission and guiding principles, see: Mission Statement, Vision, & Core Values (2026) of Guizhou Bailing Group Pharmaceutical Co., Ltd.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ): How It Makes Money

• Primary revenue drivers: manufacture and sale of finished pharmaceutical products (traditional Chinese medicine and chemical drugs), bulk drug intermediates, and related distribution services.
• Supplementary income: licensing/IP-related revenue and government/research collaboration subsidies tied to R&D and regional healthcare projects.
• Cost structure: raw materials, production and quality-control facilities, distribution/logistics, and R&D spending to defend product lines and IP.

• Market position: mid‑cap regional pharmaceutical player with a diversified product mix and recognized IP/policy credentials that support tendering and institutional contracts.
• Future outlook: growth prospects hinge on successful commercialization of R&D, margin recovery from production efficiencies, and market sentiment reflected in the stock's CN¥3.50-CN¥6.94 trading band.
• Investor signal: low historical ROE (~0.17%) indicates limited profitability per unit of equity to date; operational improvements or higher‑margin products would be needed to materially lift shareholder returns.